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Antibiotic resistance is a global public health problem that requires our attention.
Indiscriminate antibiotic use is a major contributor in the introduction of selective
pressures in our natural environments that have significantly contributed in the rapid
emergence of antibiotic-resistant microbial strains. The use of probiotics in lieu of
antibiotic therapy to address certain health conditions in both animals and humans
may alleviate these antibiotic-mediated selective pressures. Probiotic use is defined
as the actual application of live beneficial microbes to obtain a desired outcome by
preventing diseased state or improving general health. Multiple studies have confirmed
the beneficial effects of probiotic use in the health of both livestock and humans.
As such, probiotics consumption is gaining popularity worldwide. However, concerns
have been raised in the use of some probiotics strains that carry antibiotic resistance
genes themselves, as they have the potential to pass the antibiotic resistance genes to
pathogenic bacteria through horizontal gene transfer. Therefore, with the current public
health concern on antibiotic resistance globally, in this review, we underscore the need
to screen probiotic strains that are used in both livestock and human applications to
assure their safety and mitigate their potential in significantly contributing to the spread
of antibiotic resistance genes in our natural environments.
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INTRODUCTION
Since its advent, antibiotics remain as the major therapeutic strategy that is used to address
numerous diseases of infectious etiologies both in human and veterinary medicine (Drago et al.,
2011; Schjørring and Krogfelt, 2011; Verraes et al., 2013; Allen and Stanton, 2014; Card et al.,
2015). However, the indiscriminate and improper use of antibiotics has led to the decreased
susceptibility and increased resistance rates observed not only in disease-causing microbes but in
commensal microbes as well (Rosander et al., 2008; Drago et al., 2011; Allen and Stanton, 2014;
von Wintersdorff et al., 2014; Card et al., 2015). Rampant antibiotic use has pushed microbes to
adapt and survive by acquiring antibiotic resistance genes that led to antibiotic-resistant strains
(Schjørring and Krogfelt, 2011; Forslund et al., 2013; Fouhy et al., 2013; Ghosh et al., 2013; Verraes
et al., 2013; Allen and Stanton, 2014; Card et al., 2014). Antibiotic resistance genes are then
vertically passed on to the next generation of microbes; in some cases, they are acquired through
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horizontal transfer from one microbe to another, when thriving
in the same microbial environment (Schjørring and Krogfelt,
2011; Broaders et al., 2013; Forslund et al., 2013; Fouhy et al.,
2013; Ghosh et al., 2013; Verraes et al., 2013; Allen and Stanton,
2014; Card et al., 2014, 2015).
In the human clinical setting, these antibiotic-resistant
pathogens have caused numerous treatment failures that
eventually led to both hospital morbidities and mortalities
(Vankerckhoven et al., 2008; Schjørring and Krogfelt, 2011; Lu
et al., 2014). Overall, the prevalence of antibiotic resistance
has now become a global health problem that needs urgent
attention from the world health authorities (Egervärn et al., 2010;
Schjørring and Krogfelt, 2011; Ghosh et al., 2013; Penders et al.,
2013; Hu et al., 2014; Lu et al., 2014; von Wintersdorff et al.,
2014; Card et al., 2015; van Schaik, 2015). In addressing the
problem on antibiotic resistance, the use of probiotics in lieu of
antibiotics for treating certain diseases of host organisms has been
investigated (Rosander et al., 2008; Muñoz-Atienza et al., 2013).
Numerous studies have shown that instead of killing pathogenic
microbes through antibiotics, the establishment of commensal
and sometimes mutualistic microbes may hinder the growth
of disease-causing microbes found in the same host microbial
environment (Saarela et al., 2007; Hammad and Shimamoto,
2010; Klein, 2011; Nueno-Palop and Narbad, 2011; Wei et al.,
2012; Varankovich et al., 2015). In addition, it has also been
demonstrated that maintaining what is considered “normal”
microbiota for certain host microbial environments may prevent
diseased conditions that are not necessarily of infectious etiology
and may improve general health outcome (Franz et al., 2011;
Nueno-Palop and Narbad, 2011; Wei et al., 2012; Téllez et al.,
2015; Varankovich et al., 2015). As a result, probiotic use,
defined as the application of actual live beneficial microbes,
has been increasingly practiced for both human and veterinary
applications (Tompkins et al., 2008; Vankerckhoven et al., 2008;
Sanders et al., 2010; Xiao et al., 2010; Nueno-Palop and Narbad,
2011; Songisepp et al., 2012; Devi et al., 2015; D’Orazio et al.,
2015; Fuochi et al., 2015; Senan et al., 2015; Varankovich et al.,
2015). Among the modes of probiotic use, the consumption of
probiotics through the gastrointestinal route may be considered
the most common application in both human and veterinary
uses.
However, microbes used as probiotics are not exempted
from acquiring antibiotic resistance genes. Given their shared
microbial environment in the gastrointestinal tract, a risk of
pathogenic microbes acquiring antibiotic resistance genes from
probiotic microbes exists, and vice versa (Mater et al., 2007;
Rosander et al., 2008; Liu et al., 2009; Egervärn et al., 2010;
Drago et al., 2011; Nueno-Palop and Narbad, 2011; Gueimonde
et al., 2013; Varankovich et al., 2015). If improperly cooked,
livestock treated with probiotics that are consumed by humans
as food may also pose as a possible source of antibiotic resistance
genes for the human gut microbiota (Devirgiliis et al., 2011;
Schjørring and Krogfelt, 2011; Forslund et al., 2013; Verraes
et al., 2013; Allen and Stanton, 2014; Hu et al., 2014; Woolhouse
et al., 2015). To complicate the aforementioned risks, some
probiotic microbes are even screened specifically for antibiotic
resistance to be used concomitantly with antibiotics in treating
certain medical conditions (Galopin et al., 2009; Hammad and
Shimamoto, 2010). As such, there is a need to review existing
studies to clarify the safety of increasing probiotic use in relation
to the existence of antibiotic resistance genes.
This review aims to describe the processes that govern the
spread of antibiotic resistance in relation to antibiotic resistance
genes. Antibiotic resistance gene transfer in the absence of
probiotics is discussed first to elucidate the ongoing problem of
the prevalence of antibiotic-resistant bacterial strains. Probiotic
uses in both human and veterinary applications are then
described and reviewed to reaffirm their beneficial use. Screening
of probiotic bacterial strains for antibiotic resistance genes is then
discussed to evaluate the safety of probiotic use. Finally, probiotic
use in relation to the spread of antibiotic resistance genes is
tackled to clarify the potential role of probiotics in propagating
antibiotic resistance.
ANTIBIOTIC RESISTANCE
Although the remarkable increase in the incidence and
prevalence of antibiotic resistance were observed after the
introduction and widespread use of antibiotics (Datta and
Hughes, 1983; Hughes and Datta, 1983), antibiotic resistance
is believed to have existed long before human antibiotic use
(Hughes and Datta, 1983; Broaders et al., 2013). It is evident
in multiple ecological interactions, wherein many organisms,
may they be microbes or macro-organisms, have the ability to
produce natural antibiotics that ultimately increase their chances
of survival (Samuels et al., 2013; Cawoy et al., 2014; Timbermont
et al., 2014; Pinchas et al., 2015; Sherpa et al., 2015; Téllez et al.,
2015). Organisms use antibiotics to kill or inhibit growth of
pathogenic microbes, while some microbes use antibiotics to
compete for the same resources that other microbes consume
as well (Samuels et al., 2013; Timbermont et al., 2014; Pinchas
et al., 2015; Sherpa et al., 2015; Téllez et al., 2015). As a natural
evolutionary response, microbes that are able to adapt to and
survive these natural antibiotics gain advantage in producing the
next generation of microbes. Hence, antibiotic resistance is a
natural phenomenon (Sherpa et al., 2015).
Taking advantage of these ecological interactions, we have
learned to harness the use of antibiotics for a variety of
applications (Scanlon et al., 2014; Sherpa et al., 2015). We
have used antibiotics to treat infectious diseases that were
once considered very fatal, until the advent of readily available
antibiotic medications (Sherpa et al., 2015). In agriculture, we
have learned that the use of antibiotics greatly increases yield
in rearing animals primarily as food source (Allen and Stanton,
2014; Woolhouse et al., 2015; Xiao et al., 2015). Although farmers
were not entirely clear as to how antibiotic use increases growth
rates of livestock animals, they have continually used antibiotics
in sub-therapeutic doses as feeding supplements with observable
results (Allen and Stanton, 2014). In addition, infectious diseases
that once plagued farm animals are now treated successfully by
antibiotics and even prevented by prophylactic use (Allen and
Stanton, 2014; Woolhouse et al., 2015). As such, humans have
multiple reasons to use antibiotics.
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However, with rampant antibiotic use, the natural way of
developing antibiotic resistance has also changed in both manner
and rate. Due to different human applications, multiple avenues
for microbes to encounter antibiotics have put immense selective
pressure on microbes to develop antibiotic resistance (Rosander
et al., 2008; Devirgiliis et al., 2011; Drago et al., 2011; Schjørring
and Krogfelt, 2011; Forslund et al., 2013; Fouhy et al., 2013;
Ghosh et al., 2013; Verraes et al., 2013; Allen and Stanton, 2014;
Hu et al., 2014; von Wintersdorff et al., 2014; Card et al., 2015). In
turn, these have hastened the development of antibiotic-resistant
microbial strains. The rate of developing antibiotic-resistant
strains is now occurring much faster than the rate of discovering
new antibiotics (Sherpa et al., 2015).
Antibiotic Resistance Genes and the
Influence of Ecology
Just like any evolutionary response, adaptive changes of an
organism are passed on to the next generation via the organism’s
genetic material. Some microbes possess antibiotic resistance
genes that confer their ability to survive exposure to antibiotics
(Rosander et al., 2008; Drago et al., 2011; Schjørring and Krogfelt,
2011; Forslund et al., 2013; Fouhy et al., 2013; Ghosh et al.,
2013; Verraes et al., 2013; Allen and Stanton, 2014; Hu et al.,
2014; von Wintersdorff et al., 2014; Card et al., 2015). According
to the Antibiotic Resistance Gene Database, there are at least
23,317 antibiotic genes established so far, which are effective
against at least 249 known antibiotics (Hu et al., 2013). In
several recent studies, investigators have shown that the presence
of antibiotic resistance genes in microbial organisms is greatly
affected by their microbial ecology (Forslund et al., 2013; Hu et al.,
2013, 2014; Gibson et al., 2015). This observation reiterates the
natural selection pressure toward antibiotic resistance brought
about by ecological interactions found in the natural microbial
environment (Sherpa et al., 2015).
In the study of Hu et al. (2013), investigators studied
the presence of antibiotic resistance genes in the human
gut microbiota. A total of 162 individuals from China,
Denmark, and Spain were screened for antibiotic resistance
genes. It was found that a total of 1,093 antibiotic resistance
genes were present in the sample population. Antibiotic
resistance genes against three antibiotic classes – tetracycline,
macrolides, and beta-lactams – accounted for more than
75% of the total antibiotic resistance genes. Interestingly,
antibiotic resistance genes found in Chinese individuals were
statistically clustered in terms of similarity, when compared
to the two European populations that had statistically more
similar antibiotic resistance profiles. This suggests that the
actions of human hosts as a population also affect the
microbial ecology and, ultimately, the antibiotic resistance gene
profiles of the gut microbiota. In support of the previous
statement, a study of Lu et al. (2014) demonstrated that human
populations of different age groups also produced different
antibiotic resistance genes profiles that were statistically clustered
by age. Hence, different activities of different human age
groups also dictate antibiotic resistance profiles of human gut
microbiota.
In addition, Forslund et al. (2013) showed that country-
specific antibiotic use influences the antibiotic resistance genes
found in the human gut microbiota. In addition to actual medical
application of antibiotics, the investigators also considered the
antibiotics used in livestock agriculture for food production.
Investigators found that veterinary use of antibiotics also
influenced antibiotic resistance genes profile of the human gut
microbiota. This reaffirms the role of ecological interactions
among humans, animals, and the microbial environment in
influencing antibiotic resistance genes, ultimately found in the
human gut microbiota (Schjørring and Krogfelt, 2011; Hu et al.,
2014). As such, many studies recommend that in addressing
the problem on antibiotic resistance, an ecological approach
and perspective are needed as evidence suggests that antibiotic
resistance is not entirely confined to human medical antibiotic
use alone (Devirgiliis et al., 2011; Schjørring and Krogfelt, 2011;
Forslund et al., 2013; Verraes et al., 2013; Allen and Stanton,
2014; Hu et al., 2014; Woolhouse et al., 2015). Agricultural use
of antibiotics should be properly regulated as well as clinical
prescription of antibiotics in humans (Verraes et al., 2013; Allen
and Stanton, 2014; Woolhouse et al., 2015).
Antibiotic Resistance Genes and Their
Spread through Mobile Genetic Elements
As mentioned earlier, antibiotic resistance genes are vertically
transferred from one generation to another and favor the survival
of resistant microbes (Schjørring and Krogfelt, 2011; Penders
et al., 2013; Verraes et al., 2013; Allen and Stanton, 2014;
Fouhy et al., 2014; Hu et al., 2014; Card et al., 2015; van
Schaik, 2015). However, it is the ability of microbes to conduct
horizontal gene transfer that somehow complements the rampant
human antibiotic applications in hastening the development of
antibiotic-resistant strains. Horizontal gene transfer in microbes
is made possible through mobile genetic elements (Karami et al.,
2007; Mater et al., 2007; De Vries et al., 2011; Drago et al., 2011;
Haug et al., 2011; Broaders et al., 2013; Machado and Sommer,
2014; von Wintersdorff et al., 2014). The gastrointestinal tract
is a prime candidate for conducting studies on horizontal gene
transfer (Broaders et al., 2013).
In the human gastrointestinal tract, four mobile genetic
elements are considered: plasmids, conjugative transposons,
integrons, and bacteriophages (Broaders et al., 2013). Among
mobile genetic elements, only bacterial plasmids, conjugative
transposons, and integrons are considered well-established and
well-documented to cause antibiotic genes transfer in both the
natural environment and the clinical setting. It has been reported
that antibiotic resistance genes were successfully transferred from
a commensal bacterial strain to a pathogenic bacterial strain, and
vice versa, using plasmids as vectors of horizontal gene transfer
(Broaders et al., 2013). Using conjugative transposons, antibiotic
resistance to tetracycline, chloramphenicol, kanamycin, and
erythromycin are reported to be transferred in certain species of
bacteria. The loss of efficacy of tetracycline against opportunistic
Bacteroides spp. infection is specifically attributed to conjugative
transposons (Broaders et al., 2013). Integrons, which function
very similarly, like transposons, have been identified as the
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cause of spread of antibiotic resistance in Vibrio cholerae
(Broaders et al., 2013). On the other hand, the role of
bacteriophages in promoting bacterial horizontal gene transfer
is only suggested with the small but significant presence of
phage-related proteins in the human gut microbial community
(Broaders et al., 2013). Given the genetic-hacking machinery
of viruses, bacterial horizontal gene transfer brought about by
bacteriophage infection from one bacterium to another cannot
be simply ruled out.
Besides mobile genetic elements, it was suggested that perhaps
the most mobile that antibiotic resistance genes can be is through
actual travel of human hosts carrying antibiotic-resistant strains.
In the study of von Wintersdorff et al. (2014), the investigators
demonstrated that international travel of 122 healthy Dutch
travelers with documented fecal antibiotic resistance genes
profiles caused significant increases in extended spectrum beta-
lactamase-encoding genes and quinolone resistance-encoding
genes found in their gut microbiota, immediately after their
return to the Netherlands. Travel to Southeast Asia and travel to
the Indian subcontinent were the most associated with increase
in quinolone resistance-encoding genes alone, and increase in
both beta-lactamase-encoding genes and quinolone resistance-
encoding genes, respectively. In sum, these alarming findings
suggest that human travel can contribute to the global spread of
antibiotic resistance genes (von Wintersdorff et al., 2014).
Current Efforts to Control Antibiotic
Resistance
Given the ecological nature of the problem on antibiotic
resistance, several nations have adopted policies to address the
issue. Perhaps the most notable is that of the member states
of the European Union (EU). Since 2006, all EU countries
have prohibited the use of antibiotics for the sole purpose of
growth promotion in agricultural livestock industry (Cogliani
et al., 2011). In addition, the European Food Safety Authority
(EFSA) has instituted guidelines on the use of food additives in
animal products that may potentially spread antibiotic resistance
genes (Panel, 2012). However, other developed nations, such
as the United States (US), has not imposed strict regulatory
policies on antibiotic use for livestock growth promotion.
Animal food and pharmaceutical industries in the US have
strongly opposed restrictions in antibiotic use and have argued
that such policies have been detrimental to food production
in places where they were implemented. Furthermore, some
countries do not have any known or established policy regarding
the use of antibiotics as growth promoters, nor even require
veterinary prescription for animal antibiotic use (Maron et al.,
2013).
With the current paucity of clear regulatory policies in many
countries, a global effort is needed in order to consolidate an
effective strategy in controlling antibiotic resistance. Without a
unifying regulatory guideline to follow, the problem on antibiotic
resistance will most likely persist given the interweaving
ecological interactions that govern the spread of antibiotic
resistance. Furthermore, the spread of antibiotic resistance genes
through human travel or trading of animal products between
nations may make instituted regulatory policies of some countries
less effective.
USE OF PROBIOTICS
As the development of antibiotic resistance strains continues,
the use of probiotics as a substitute for antibiotics is becoming
more popular in both the medical field and livestock agriculture
(Collins and Gibson, 1999; Collado et al., 2012; Muñoz-
Atienza et al., 2013; D’Orazio et al., 2015; Téllez et al., 2015;
Varankovich et al., 2015). Probiotic use is defined as the actual
application of live beneficial microbes to obtain a desired
outcome, may it be prevention of a diseased state or improvement
in general health outcome observed in the host organism
(Collins and Gibson, 1999). The basis of its efficacy relies on
the symbiosis of an established microbial ecology that resists
the intrusion or overproduction of pathogens that lead to a
diseased condition of the host organism (Catanzaro and Green,
1997). By limiting the use of antibiotics, probiotic use may help
decrease the rate of development of antibiotic-resistant strains
secondary to widespread and rampant antibiotic use (Collins and
Gibson, 1999; Collado et al., 2012; Muñoz-Atienza et al., 2013;
Varankovich et al., 2015).
Probiotics and Livestock Benefits
Many farm animals are considered to be adapted in a
symbiotic relationship with microbes as shown by specialized
gastrointestinal organs that enable microbial fermentation (Téllez
et al., 2015). The capacity of farm animals to ferment complex
polysaccharides with the help of their intestinal microbiota gives
as much as 70% of energy acquired by ruminants and up to
30% of energy acquired by monogastric animals (Téllez et al.,
2015). However, it is only fairly recent that this symbiotic
relationship between farm animals and their microbiota is taken
advantage of by farmers with the use of probiotics. With the
increasing problem on antibiotic resistance, studies have shown
that probiotic use can replace antibiotics in preventing diseased
conditions and promoting growth in livestock animals (Muñoz-
Atienza et al., 2013; Téllez et al., 2015).
Probiotic use in livestock agriculture of chickens and
turkeys has been demonstrated to confer increased resistance
in Salmonella spp. infections through accelerated establishment
of what is considered normal and healthy microbiota for the
aforementioned birds (Téllez et al., 2015). In addition, the
incidence of idiopathic diarrhea in commercial turkey brooding
houses was reported to be decreased by probiotic use (Téllez et al.,
2015). As a whole, large-scale commercial trials of appropriate
probiotic administration in chickens and turkeys demonstrated
increased performance and reduced overall costs of production
(Téllez et al., 2015).
In cattle raising, it was reported that probiotic use provided
no significant effects in reducing cattle pathogens (Téllez
et al., 2015). However, Escherichia coli O157:H7, a food-borne
pathogen capable of causing severe hemorrhagic illness in
humans, was known to be shed by livestock animals in their
feces. With the use of different combinations of bacteria used
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as probiotics, it was shown that there was decreased shedding
of E. coli O157:H7 in both cattle and sheep livestock that may
translate to decreased risk of E. coli O157:H7 human infections
(Téllez et al., 2015).
Even in a different habitat such as in aquaculture, probiotic
use has also been gaining ground. In the study of Muñoz-
Atienza et al. (2013), it was demonstrated that lactic acid-
producing bacteria of aquatic origin can exhibit antimicrobial
activity against established gram-positive and gram-negative fish
pathogens. However, no comprehensive in vivo assessment has
yet to determine the beneficial and possible harmful effects of
probiotic use in aquaculture (Muñoz-Atienza et al., 2013).
Probiotics and Human Health
For humans, probiotic use has become a popular practice for
promoting good health. Many commercial food products are
now being supplemented by probiotic bacteria with claims of
promoting good health (Songisepp et al., 2012). It is no surprise
that there is an increasing number of probiotic users as we begin
to understand better the role and importance of human gut
microbiota, as well as what is considered to be “normal” and
symbiotic human gut microbiota (Catanzaro and Green, 1997;
Collins and Gibson, 1999; Collado et al., 2012).
The complex microbiota of the human gut is considered to
play important roles in several gastrointestinal functions. These
functions include host nutrition, regulation of gut epithelial
development, regulation of fat storage, stimulation of intestinal
angiogenesis, inflammatory immune response, and pathogen
resistance (Collins and Gibson, 1999; Ventura et al., 2009).
In parallel comparisons with the macro-ecosystems of the
natural environment, we can deduce that the more stable the
composition of the human gut microbiota is, the more beneficial
it is for the human host habitat. Indeed, there are expected human
gut microbiota profiles that are considered to be symbiotic and
are indicators of good health (Varankovich et al., 2015). This
is supported by associations demonstrated between deviations
in the composition of symbiotic adult pattern of human gut
microbiota and a variety of human medical conditions such as
inflammatory bowel disease, allergy, obesity, and atopic disease
(Ventura et al., 2009).
Looking at current human medical applications, probiotic
use is clinically proven to modulate infant gut microflora
disturbance after antibiotic use (Collado et al., 2012). The
use of antibiotics early in the infant’s life is considered
detrimental to infant gut microbial diversity, as antibiotics do
not discriminate in killing microorganisms that are affected
by the antibiotics’ mechanism of action. As such, normal gut
microbiota composed of commensal and beneficial microbes is
decreased in the infant’s gut, allowing the potential increase
in the population of harmful microbes that are not affected
by the antibiotics’ mechanism of action. This process leads
to diseased conditions associated with antibiotic use such as
antibiotic-induced diarrhea (Collins and Gibson, 1999; Collado
et al., 2012; Varankovich et al., 2015). In addition, perinatal and
postnatal probiotic use are reported to have potential benefits
in preventing future developments of allergies (Kukkonen
et al., 2007), asthma (Luoto et al., 2010), gastrointestinal
infections (Johnston et al., 2007), and obesity (Vliagoftis
et al., 2008), as the aforementioned diseased conditions are
all associated with the interplay of gut microbiota and the
development of the host immune system (Collado et al., 2012). By
disturbing the infant’s gut microbiota, antibiotics pose a potential
risk in pre-disposing infants to the aforementioned diseased
conditions.
Unlike in infants, human adults with consistent oral intake
of established probiotics have not yet shown clinically significant
changes in adult gut microbiota composition, structure, and gene
content (Ursell et al., 2013). However, for a specific medical
condition, such as Clostridium difficile-associated diarrhea,
studies have shown that probiotic use, sometimes in the extreme
form of fecal transplantation, effectively addresses recurrent
C. difficile-associated diarrhea (Ursell et al., 2013; Van den
Abbeele et al., 2013; Varankovich et al., 2015). C. difficile-
associated diarrhea is a disease associated with prolonged
antibiotic use which kills normal human gut microbiota that
supposedly hinders the growth of the C. difficile population (Van
den Abbeele et al., 2013; Varankovich et al., 2015).
There are other human medical conditions now being
connected to the human gut microbiota. Interestingly, these
medical conditions associated with human gut microbiota are
not confined to diseases with infectious etiologies (Ventura
et al., 2009). Common medical conditions with established
non-microbial pathophysiologies, such as obesity and diabetes
mellitus, and much rarer gastrointestinal disorders, such as
irritable bowel syndrome, Crohn’s disease, and necrotizing
enterocolitis, are presently being associated with dysbiosis in the
human gut microbiota (Peterson et al., 2008; Emami et al., 2009;
Serino et al., 2009; Salonen et al., 2010; Angelakis et al., 2012;
Snedeker and Hay, 2012; Jeffery and O’Toole, 2013). Deviation
from what is accepted to be “normal” human gut microbial
ecology appears to be part of the aforementioned diseases’
pathophysiologies. Therefore, more medical applications of
probiotic use to maintain normal human gut microbial ecology
are anticipated to appear in the near future.
SAFETY OF PROBIOTIC USE
Microbes used as probiotics are not exempted from the natural
processes governing antibiotic resistance (Mater et al., 2007;
Rosander et al., 2008; Chang et al., 2009; Egervärn et al., 2010;
Drago et al., 2011; Nueno-Palop and Narbad, 2011; Gueimonde
et al., 2013; Varankovich et al., 2015).
As such, it is imperative to screen microbes effectively for
antibiotic resistance genes before using them as probiotics.
A crucial aspect in studying antibiotic resistance in probiotic
bacteria is to separate intrinsic resistance from acquired
resistance (Sanders et al., 2010). Mechanisms of intrinsic
resistance, such as active eﬄux of antibiotics by a bacterial outer
membrane, is not governed by acquired antibiotic resistance
genes (Chang et al., 2009; Hammad and Shimamoto, 2010).
Focusing on acquired antibiotic resistance, random genetic
changes on chromosomal genes should be further distinguished
from the more likely transmissible type of antibiotic resistance.
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However, to our knowledge, no unified world-wide health
authority has taken full responsibility in screening for antibiotic
resistance genes in probiotic microorganisms. Fortunately,
research projects, such as the Biosafety Assessment of Probiotics
used for Human Consumption (PROSAFE), the Assessment
and Critical Evaluation of Antibiotic Resistance Transferability
in Food Chain (ACE-ART), and the Joint International
Organization for Standardization-International Dairy Federation
Action Team on Probiotics (ISO-IDF) have individually
contributed to address the issue (Sanders et al., 2010). In
evaluating the safety of potential probiotic strains, two statuses
are currently acceptable – Qualified Presumption of Safety
(QPS) by the EFSA and Generally Recognized as Safe (GRAS)
by the US-FDA. It is noteworthy that GRAS status is applied to
microorganisms and microbial-derived ingredients used in food
products while QPS is applied to any biological agent in the form
of bacteria, fungi, or virus, that is intentionally added at different
stages into the food chain. However, the QPS is considered
by many as the more applicable and flexible criteria, given the
emerging risk of spreading antibiotic resistance genes through
probiotic strains (Sanders et al., 2010).
In the paper of Sanders et al. (2010), a case was discussed
wherein the outcomes of aforementioned standards for
evaluating potential probiotics were not consistent. The case
involved the use of a probiotic bacteria intended for infant-
formula that claims improved growth in developing infants. Both
standards were aware that the probiotic strain involved carries a
chromosomal gene for tetracycline resistance. Using the GRAS
criteria, the US FDA evaluated the “safety of probiotic use” with
“reasonable certainty,” while the European counterpart cited
“safety of probiotic use in light of the strength or weakness of
the evidence for benefit” and “the lack of knowledge necessitates
application of precautionary principles.” As such, the US FDA
granted GRAS status to the involved probiotic strain, while the
EFSA did not grant QPS status.
Given the separate approaches in screening probiotic bacterial
strains, multiple independent studies have demonstrated several
methods in screening different probiotic strains for antibiotic
resistance genes (Tompkins et al., 2008; Vankerckhoven et al.,
2008; Chang et al., 2009; Galopin et al., 2009; Xiao et al., 2010;
Klein, 2011; Nueno-Palop and Narbad, 2011; Cebrián et al., 2012;
Songisepp et al., 2012; Wei et al., 2012; Tan et al., 2013; Devi
et al., 2015; Senan et al., 2015). In places where it is not bound
to either US FDA or EFSA, screening for antibiotic resistance
genes in probiotic strains becomes even more important as rigid
guidelines and regulations for probiotic use are lacking (Chang
et al., 2009).
Lactic Acid Bacteria and Their Safety
Profile
The most common group of bacteria used as probiotics belongs
to the group of lactic acid bacteria (Gueimonde et al., 2013;
Varankovich et al., 2015). Included in this group are Lactobacillus
and Enterococcus. Both genera are currently extensively screened
for species that can be used as probiotic bacteria (Tompkins et al.,
2008; Vankerckhoven et al., 2008; Chang et al., 2009; Klein, 2011;
Nueno-Palop and Narbad, 2011; Cebrián et al., 2012; Songisepp
et al., 2012; Tan et al., 2013; Devi et al., 2015; Senan et al., 2015).
Lactobacillus probiotic strains are capable of improving
digestion, absorption, and availability of nutrients in both
livestock animals and humans (Téllez et al., 2015; Varankovich
et al., 2015). They are also known to inhibit and kill Helicobacter
pylori, a pathogen regarded as the major cause of gastritis and
peptic ulcers, and is a risk factor for gastric malignancy in
humans (Varankovich et al., 2015). In addition, the risk of human
infectious disease due to Lactobacillus is considered negligible at
less than one case per million individuals (Sanders et al., 2010).
Enterococcus probiotic strains are also known to be effective
in reducing recovery periods of acute diarrhea in both animals
and humans (Vankerckhoven et al., 2008; Varankovich et al.,
2015). However, unlike Lactobacillus, the genus Enterococcus has
member strains that are considered opportunistic pathogens and
are sometimes the etiologic agents of some human nosocomial
infections, such as bacteremia and infective endocarditis
(Vankerckhoven et al., 2008; Sanders et al., 2010; Franz et al.,
2011; Varankovich et al., 2015).
It has also been reported in several studies that some
species of lactic acid bacteria have intrinsic resistance to
bacitracin, kanamycin, teicoplanin, vancomycin, and beta-
lactams (Varankovich et al., 2015). Given the beneficial effects
of lactic acid bacteria, intrinsic resistance to certain antibiotics
may be considered advantageous if an antibiotic-probiotic
combination therapy is desired (Hammad and Shimamoto,
2010; Varankovich et al., 2015). In the study of Hammad
and Shimamoto (2010), investigators deliberately screened for
antibiotic-resistant probiotic strains in 40 commercially available
Japanese probiotic supplements, which are to be used with
a possible probiotic-antibiotic combination therapy. However,
results showed no antibiotic resistance genes found in their
isolates. As such, no isolated probiotic strain was reported feasible
for a probiotic-antibiotic combination therapy.
Due to horizontal gene transfer, concerns are still raised
particularly in lactic acid bacteria strains that carry mobile genetic
elements such as plasmids (Varankovich et al., 2015). In the
study of Mater et al. (2007), in vivo transfer of the vancomycin
resistance gene, a plasmid encoded gene, was successfully
demonstrated between lactic acid bacteria Enterococcus faecium
strains and Lactobacillus acidophilus probiotic strains during
digestive transit in mice. The results highlighted the risk of
probiotics being a conduit for the spread of antibiotic resistance
(Mater et al., 2007).
In the study of Chang et al. (2009), it was found that
commercially available food and drugs with probiotic additives
contained lactic acid bacteria strains positive for antibiotic
resistance genes. Although the incidence of the antibiotic
resistance genes was relatively low among the sample population,
the antibiotic resistance genes found in the probiotic strains
were located in mobile genetic elements such as plasmids and
transposons. Despite the GRAS status of the specified lactic
acid bacteria strains, the study’s findings confirm the threat
of spreading antibiotic resistance genes through the use of
probiotics. This is especially the case in countries without
established guidelines and regulations in biosafety testing and
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FIGURE 1 | Skewing the double-edged effects of probiotics toward positive outcomes.
rigid post-marketing surveillance. As such, a regulatory body, if
not a united world-wide health authority, should always be in
place to rigidly monitor probiotic use in every country (Chang
et al., 2009).
Bifidobacteria and Their Safety Profile
Another group of bacteria commonly used as probiotics belong to
the genus Bifidobacterium (Gueimonde et al., 2013; Varankovich
et al., 2015). Bifidobacterium is a known major constituent of
the gut microbiota of both animals and humans. Bifidobacteria
have the capacity to metabolize non-digestable host dietary
carbohydrates such as plant-derived dietary fiber.
As a probiotic, strains of Bifidobacterium are known to
inhibit adherence of enterotoxigenic E. coli, enteropathogenic
E. coli, and C. difficile to intestinal epithelial cells (Varankovich
et al., 2015). In combination with Lactobacillus, Bifidobacterium
was shown to alleviate side effects of H. pylori eradication
therapy as some Bifidobacterium strains also suppress H. pylori-
induced genes in human epithelial cells (Varankovich et al.,
2015). In addition, Bifidobacterium strains are also known to
alleviate infectious diarrhea as well as inflammatory bowel disease
(Varankovich et al., 2015). Like Lactobacillus, infectious diseases
due to Bifidobacterium are extremely rare (Gueimonde et al.,
2013).
Bifidobacterium strains are known to have intrinsic resistance
against ciprofloxacin, nalidixic acid, mupirocin, streptomycin,
and aminoglycosides (Wei et al., 2012; Gueimonde et al.,
2013; Varankovich et al., 2015). However, resistance genes for
lincosamides, macrolides, streptogramin B, and tetracycline are
reported to be located in transposons (Gueimonde et al., 2013).
In the study of Xiao et al. (2010), investigators tested the
antibiotic susceptibility of Bifidobacterium strains distributed in
the Japanese market. A total of 23 Bifidobacterium strains were
isolated and tested for 15 antibiotics. Results confirmed the
intrinsic resistance of Bifidobacterium against aminoglycosides.
However, Bifidobacterium animalis subsp. lactis was found
to be resistant to tetracycline and was in fact harboring a
tetracycline resistance gene in its chromosome. The study
concluded that although there is no risk factor for safety found
in Bifidobacterium strains distributed in the Japanese market, the
presence of the tetracycline resistance gene stresses the need for
future evaluation (Xiao et al., 2010).
Miscellaneous Concerns
The problem with the absence of a unified world-wide health
authority that assumes responsibility for regulating probiotic use
is exemplified by the case mentioned in the paper of Sanders
et al. (2010). In countries with no established regulating body
for probiotic use, the result is even worse as exemplified by the
study of Chang et al. (2009). Keeping in mind that the likelihood
of the spread of antibiotic resistance genes through human
international travel was clearly indicated in the study of von
Wintersdorff et al. (2014), we believe that a united global effort
to screen probiotics that are marketed for human consumption is
imperative.
In addition, given the established ecological nature of the
emergence of antibiotic resistance problem, it is deemed logical
to deduce that regulating probiotic use should also involve an
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ecological approach. It should be noted that studies involving the
regulation of probiotic use in animals are lacking when compared
to those of human applications. We should be reminded that
numerous studies have already shown the connection between
antibiotic resistance genes in animals and those in humans
(Devirgiliis et al., 2011; Schjørring and Krogfelt, 2011; Forslund
et al., 2013; Verraes et al., 2013; Allen and Stanton, 2014; Hu et al.,
2014; Woolhouse et al., 2015). Without addressing regulations
in animal probiotic applications, efforts in regulating human
probiotic use might be considered inadequate in the end.
CONCLUSION
The emergence of antibiotic resistant pathogens through the
spread of antibiotic resistance genes is an ecological problem
that is exacerbated by the widespread indiscriminate use of
antibiotics in livestock agriculture, and in veterinary and human
medicine. The use of probiotics in lieu of antibiotics to
control some diseases in animals and humans may reduce the
antibiotic selective pressures on microorganisms in our natural
environments and contribute in reducing the problem of the
rapid emergence of antibiotic resistant pathogens. However,
probiotic bacterial strains used in both animal and human
applications also have risks in becoming conduits themselves in
spreading antibiotic resistance genes. We conclude that the use of
probiotics to address the global problem of emerging antibiotic
resistant microorganisms is a “double-edged” sword – with both
beneficial effects and associated risks as depicted in Figure 1.
Therefore, although probiotics are currently generally regarded
as safe, we think that it is imperative to implement proper
regulation on their use in both livestock and human applications
globally to effectively mitigate their potential contribution
in the spread of antibiotic resistance genes in our natural
environments.
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